

La Renon

Rise  
above the rest



PRESENTING FOR THE FIRST TIME IN INDIA

**Larinject She 4 ml** [ 200 mg ]

Ferric Carboxymaltose Injection 50 mg/ml

ALSO AVAILABLE IN 10 ml VIAL

# Larinject She

Ferric Carboxymaltose Injection 50 mg/ml ( 4 ml Vial & 10 ml Vial )

Ris

Ferric Carboxymaltose (FCM) a novel iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell, allows for controlled delivery of iron to target tissues.



## PROPERTIES OF IV

Property	Iron Sucrose	Ferric Carboxymaltose
Carbohydrate Shell	Sucrose (disaccharide)	Carboxymaltose
Complex Type	Type II Semi Robust & moderately strong	Type I Robust & Strong
Molecular Weight (kD)	30-60	150
Plasma Half Life	6 Hr	16 Hr
Labile Iron Release	Present	Nearly absent
Direct Iron Donation to Transferrin (% injected dose )	4 - 5	1 - 2
Test dose required	No	No



## Clinical Evidence

### AIM:

To investigate the safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis

### Study Design:

Multi-Centre, Open-label, Clinical study

### Dose:


Patients (aged 18–65 years) received 100 – 200 mg of iron as FCM

### Study Endpoint:

Haemoglobin (Hb), Serum Ferritin, TSAT

### Result:

Mean Hb levels with FCM 200 mg increased from  $9.1 \pm 1.30$  g/dl at baseline to  $10.3 \pm 1.63$  g/dl at follow-up



Within the 2 weeks following the first administration of FCM, serum ferritin levels and TSAT had increased to within their respective target ranges ( $200\text{--}500 \mu\text{g/l}$  serum ferritin and  $>20\%$  TSAT) for patients undergoing HD ( $512.7 \pm 241.36 \mu\text{g/l}$  and  $38.4 \pm 17.23\%$ , respectively) and, although decreasing slightly, remained in the target range until the final follow-up visit ( $333.6 \pm 209.05 \mu\text{g/l}$  and  $31.0 \pm 11.00\%$ , respectively)

### Conclusion:

FCM is well-tolerated and effective in the correction of Hb levels and iron stores.



# To Avoid Multiple Dosage of Iron Sucrose Presenting

## Larinject She 4 ml [ 200 mg ]

Ferric Carboxymaltose Injection 50 mg/ml

ALSO AVAILABLE IN 10 ml VIAL

### Description:

Larinject she is an intravenous iron preparation, a medicine that is used in the treatment of iron deficiency conditions.

### Indication:

For the treatment of Iron deficiency (ID) and iron deficiency anemia (IDA) in adults who have intolerance to oral iron or who have had unsatisfactory response to oral iron

### Dosage & Administration:

Larinject She (Ferric Carboxymaltose) must only be administered by the intravenous route: by injection, by infusion.

### Dilution plan of Larinject She Injection for intravenous drip infusion

Ferric Carboxymaltose	Iron	Maximum amount of sterile 0.9% NaCl solution	Minimum administration time
2 to 4 mL	100 to 200 mg	50 ml	
>4 to 10 mL	>200 to 500 mg	100 ml	6 minutes
>10 to 20 mL	>500 to 1,000 mg	250 ml	15 minutes

### Presentation:

Larinject she is available as a Vial of 4 ml and 10 ml.



La Renon Healthcare Private Limited

207-208 ISCON Elegance | Circle P | Prahlad Nagar Cross Roads S.G.Highway  
Ahmedabad - 380015 | Gujarat | India.  
Phone: +91-79-6616-8998, +91-79-2693-6656 | Fax: +91-79-6616-8998  
E-Mail: info@larenon.com | www.larenon.com

©2023 All rights reserved, La Renon Healthcare Private Limited



I Am \_\_\_\_\_  
Call Me On \_\_\_\_\_  
Mail Me At \_\_\_\_\_